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KINETOPLASTIDA: NEW THERAPEUTIC STRATEGIES
CROFT S.L.*
Summary: 
New formulations and therapeutic switching of the established
drugs, amphotericin B and paromomycin, together with the
discovery of miltefosine, have significantly improved the
opportunities for treatment of visceral leishmaniasis (VL)
chemotherapy. However, for human African trypanosomiasis
(HAT), Chagas disease and cutaneous leishmaniases there has
been limited progress. For HAT, a novel diamidine, parfuramidine,
is in phase III clinical trial for early-stage disease, but for the
treatment of late-stage disease there are no new drugs and
combinations of eflornithine with melarsoprol or nifurtimox have
been the focus of clinical studies. For Chagas disease, different
classes of compounds that have validated biochemical targets,
sterol biosynthesis methylases and cysteine proteases, are in
various stages of development. The genome sequences that are
now available for the pathogens that cause the leishmaniases and
trypanosomiases, and new methods for rapid validation of targets,
are part of the solution to discover new drugs. The integration of
medicinal chemistry, pharmacokinetics, project planning and
interaction with the pharma/biotech sector are essential if progress
is to be made. Although there are financial constraints, the
appearance of new funding sources and not-for-profit product
development partnerships offers hope for drug development.
KEY WORDS : visceral leishmaniasis, cutaneous leishmaniasis, human African
trypanosomiasis, Chagas disease, drugs, chemotherapy.
* Department of Infectious and Tropical Diseases, London School
of Hygiene & Tropical Medicine, London WC1E 7HT, UK.
E-mail: simon.croft@lshtm.ac.uk
New and established pharmacophores, based upon
synthetic and natural product chemistry, have to be
brought into place along with improved screening
technologies to identify hits (Frearson et al., 2007).
Appropriate models of infection and early pharmaco-
kinetic studies to evaluate leads, also need to be inte-
grated into the process, as seen at academic centres in
USA (www.ucsf.edu/mckerrow) and UK (www.dun-
dee.ac.uk/biocentre). The support of public-private
partnerships like the Drugs for Neglected Diseases ini-
tiative (www.dndi.org) and interaction with the com-
mercial sector is also required. Further development
will depend upon the expertise in lead optimization,
toxicology and pharmacology available in the pharma-
ceutical and biotech sectors and CROs with the associa-
ted requirement for high level funding (see for example
www.dndi.org). Clinical trials capacity is also required
and is being addressed in India, Africa (www.sti.ch)
and South America. The issues around drug produc-
tion and delivery also need to be addressed; the
example of paromomycin delivery for VL in India pro-
vides some model for the future (www.iowh.org).
LEISHMANIASIS
There have been different rates of developmentand there are different issues associated withdrug development for visceral leishmaniasis (VL)
and cutaneous leishmaniasis (CL); these two manifes-
tations will therefore be treated separately.
VISCERAL LEISHMANIASIS
Pentavalent antimonials, the standards drugs for 60 years,
are now almost obsolete in India due to drug resis-
tance (Croft et al., 2006), but are still useful in the rest
of the world. The introduction of generic brands has
reduced costs. Amphotericin B, normally considered a
second line drug, is now first line in Bihar state, India.
Although a number of amphotericin B lipid formula-
tions, developed during the 1980s for treatment of sys-
temic mycoses in immunocompromised patients, have
proved effective in the treatment of VL, only one of
The drugs used for treatment of the leishma-niases and the trypanosomiases (see Table I) arefraught with problems of toxicity, variable effi-
cacy, parenteral administration or length of treatment.
For the trypanosomiases and cutaneous leishmaniasis,
there are limited drugs or treatments in clinical deve-
lopment. In contrast, for visceral leishmaniasis there has
been some progress with the availability of liposomal
amphotericin B, miltefosine and paromomycin for treat-
ment in India. Although considerable advances in the
identification, validation and characterization of drug
targets has come with the completion of the genomes
for Trypanosoma cruzi, Trypanosoma brucei and Leish-
mania major (Berriman et al., 2005) and new tools such
as RNAi (Balana-Fouce & Reguera, 2007) have been
developed, this is only one early part of the long and
complex process of drug discovery and development.
Article available at http://www.parasite-journal.org or http://dx.doi.org/10.1051/parasite/2008153522
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these, the liposomal formulation AmBisome, has
become a standard. It is registered for the treatment
of VL in various countries, its use is described by a
WHO working group (Bern et al., 2006) and a single
dose therapy of 5 mg/kg has been shown to cure 90 %
patients in India (Sundar et al., 2003). A significant
reduction in price negotiated by WHO with the pro-
ducers (Gilead) will have an impact, but AmBisome
will remain an expensive treatment. A parenteral for-
mulation of the aminoglycoside paromomycin, has
moved slowly through clinical trials over the past
decades, more recently showing 94 % efficacy (15 mg/
kg for 21 days) in phase III clinical trials in India (Sun-
dar et al., 2007) and was registered there for VL in
2006. Like paromomycin, the anti-leishmanial activity
of the phospholipid derivative, miltefosine (Fig. 1) was
first identified at the Wellcome laboratories, UK. (Croft
& Engel, 2006). This drug has provided the first oral
treatment for VL and the first to undergo phase IV stu-
dies (Bhattacharya et al., 2007).
Other opportunities remain. Rational approaches, pyra-
zolopyrimidines (allopurinol and derivatives) that dis-
rupt purine-salvage and nucleic acid biosynthesis, and
the inhibitors of 14-α demethylase and sterol biosyn-
thesis (antifungal azoles), proved to have disappoin-
ting efficacy, due to poor pharmacokinetic properties
Drugs Comments
Visceral leishmaniasis
First line drugs Sodium stibogluconate (Pentostam and SSG) Generic sodium stibogluconate (SSG) from
Meglumine antimoniate (Glucantime) Albert David (India) has made treatment 
cheaper. Sanofi-Aventis have also reduced 
the price of Glucantime
Amphotericin B (Fungizone)
Liposomal amphotericin B (AmBisome) This has proved to be the most effective
and least toxic lipid formulation for VL
Miltefosine Registered in India and available on private
market. Cheaper price available via WHO
Clinical trials Paromomycin In phase IV trials in India
Sitamaquine Completed phase II trials in India
Other amphotericin B formulations Further pre-clinical research for development
of cheaper formulations
Cutaneous leishmaniasis
First line drugs Sodium stibogluconate (Pentostam)
Meglumine antimoniate (Glucantime)
Amphotericin B (Fungizone) For complex manifestations, like mucosal 
leishmaniasis
Pentamidine For specific forms in South America
Paromomycin (topical formulation)
Clinical trials Paromomycin (topical formulations, phases II Formulations from WRAIR (Washington)
and III) and FioCruz (Belo Horizonte) on trial
Miltefosine (oral, phase III) There appears to be differences in species
sensitivity. Registered in Colombia 
Imiquimod (topical immunomodulator, As an adjunt therapy to antimonials. Reported
phase II) not to be effective in Iran
Human African trypanosomiasis
• Haemolymphatic stage
First line drugs Pentamidine
Suramin
Clinical Trial Parfuramidine (DB289) Phase III trials in DRC and Sudan
• CNS stage
First line drugs Melarsoprol
Eflornithine
Clinical Trial Nifurtimox and eflornithine co-administration Phase III trial with DNDi and WHO TDR
Chagas disease
First line drugs 
• Acute stage Nifurtimox
Benznidazole
• Indeterminate stage No treatment
• Chronic stage No treatment
Clinical trials Benznidazole BENEFIT trial for indeterminate stage
Table I. - Drugs in use or on clinical trial in 2007.
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(Shapiro et al., 1991) or biochemical routes permitting
bypass in intracellular parasites (Roberts et al., 2003).
However, allopurinol remains a component of treat-
ment of canine VL and the triazole posoconazole was
effective in rodent models (Al-Abdely et al., 1999).
Natural product screens have identified chalcones (Zhai
et al., 1999), maesabalides (Maes et al., 2004), and
novel quinolines (Nakayama et al., 2006) with activity
in rodent VL models, although metabolic and toxic lia-
bilities have limited the progress of lead compounds.
Other opportunities lie in understanding of metabolic
pathways and enzyme targets, with studies on isopre-
noid biosynthesis leading to studies on bisphospho-
nates (Yardley et al., 2002), and on kinases to paul-
lones (Grant et al., 2004).
CUTANEOUS LEISHMANIASIS (CL)
In comparison to VL there are limited proven options
for CL (see Table I). Pentavalent antimonials have pro-
ved inconsistent in their effectiveness across the diffe-
rent Leishmania species (Croft et al., 2006), and pen-
tamidine and amphotericin B are limited to specific
types of CL (see Alvar et al., 2006). Paromomycin in
various topical formulations has variable efficacy (see
Garnier & Croft, 2002), and there is a continuing search
for more effective and less irritant topical creams and
gels (Ben-Salah et al., 2005). Oral miltefosine also has
some variable, species dependent effectiveness against
CL (Soto et al., 2004: Yardley et al., 2005) and is now
registered for this indication in Colombia (2005). Fur-
ther studies are required to define effectiveness against
different forms of this disease.
HUMAN AFRICAN TRYPANOSOMIASIS
Significant advances in our understanding of thebiology of Trypanosoma brucei have not yet ledto new drugs (Berriman et al., 2005). Since the
registration of the ornithine decarboxylase inhibitor,
eflornithine, in 1990 for late stage gambiense disease
(Burri & Brun, 2003) no novel treatments have been
introduced. The lower incidence and severity of adverse
effects of eflornithine when compared to melarsoprol,
has led some to advocate that this drug should become
the first line treatment for late stage HAT (Chappuis et
al., 2005). The requirement for high doses and pro-
longed intravenous infusion, however make the drug
expensive and difficult to distribute and administer in
rural Africa. Its availability as a trypanocide is depen-
dent upon commitments made to MSF and WHO by
the manufacturing company (Sanofi-Aventis). There
have been other approaches to improve the use of cur-
rently registered drugs. Pharmacokinetic studies of
melarsoprol led to the successful testing of a shortened
Fig. 1. – New drugs in clinical or pre-clinical development for the
trypanosomiases and leishmaniasis
(a) Miltefosine, an alkylphosphocholine, originally developed as an
anti-cancer agent, subsequently developed for treatment of both VL
and CL by Zentaris AG (Germany) and WHO/TDR.
(b) Eflornithine, difluormethylornithine, an irreversible inhibitor of
ornithine decarboxylase and polyamine biosynthesis, originally deve-
loped as an anti-cancer agent, but used for the treatment of CNS
stage T. b. gambiense infection.
(c) DB 289, a diamidine, pro-drug of 2,5-bis(4-amidinophenyl)furan
(DB75 or furamidine), currently in phase III clinical trials for treat-
ment of haemolymphatic stage T. b. gambiense infection in central
Africa, in development with N. Carolina University Gates Consor-
tium.
(d) Posaconazole, a triazole derivative, that inhibits Trypanosoma
cruzi sterol C14α sterol demethylase and can eradicate the parasite
from animal models of both acute and chronic Chagas disease. Regis-
tered as a systemic antifungal agent.
(e) K777 (N-methyl-piperazine-urea-F-hF-vinyl-sulfone-phenyl), a
specific inhibitor of cruzipain, an essential cysteine protease of Try-
panosoma cruzi, with trypanocidal activity, both in vitro and in vivo.
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10 day course (rather than 21-35 days) which improves
patient compliance and reduces hospital costs (Schmidt
et al., 2004). Studies aimed to modify dosing with eflor-
nithine are also underway with clinical studies on co-
administrations with melarsprol or nifurtimox recently
reported. These studies are essential in the face of the
increased incidence of treatment failure with melarso-
prol in some HAT foci (Brun et al., 2001). Field studies
to determine the cause of these failures are of impor-
tance and are in progress.
There is only one drug currently in clinical trials. The
orally available prodrug, parfuramidine (DB289) (Fig. 1),
is converted systemically into another diamidine (fura-
midine, DB75) that is active against early stage disease
(Ansede et al., 2004). The blood brain barrier remains
a challenge in drug design to ensure sufficient drugs
reaches parasites within the brain of late stage patients.
A large number of diamidines have been synthesized
through a consortium led by the University of North
Carolina (funded by the Bill and Melinda Gates Foun-
dation) and other pro-drugs from the same series
active against late stage disease have emerged. Trypa-
nosomes are highly sensitive to selected nitrohetero-
cyclic compounds that have shown activity against CNS
stage infections in experimental models. Although cli-
nical studies have suggested that the nitrofuran nifur-
timox is insufficiently active alone for treatment of
HAT, studies have ensured that this drug is tested in
combination (ibid) and that other potent and less geno-
toxic compounds are sought (Stewart et al., 2004 and
www.dndi.org).
Research on unique metabolic targets in trypanosomes
(Berriman et al., 2005), including that around thiol
metabolism, in particular on trypanothione reductase,
on energy metabolism, in particular on glycosomal
enzymes, and on polyamine metabolism, with inter-
esting novel compounds identified but without any
clear candidates for lead optimization emerging (see
Luscher et al., 2007). The lack of advances in treatment
for HAT highlight the need for closer integration of
chemistry and biology efforts and improved unders-
tanding of the pharmacokinetic and pharmacodynamic
requirements of the ideal drug.
SOUTH AMERICAN TRYPANOSOMIASIS
(CHAGAS DISEASE)
Similar to above, despite the impressive advancesin our knowledge about the biology of T. cruzi(El-Sayed et al., 2005), the only drugs currently
available are the nitrofuran nifurtimox and the 2-benzi-
midazole benznidazole, which were developed 1960’s
and 1970’s. These drugs are active in the acute stage
of the disease (up to 80 % efficacy) but of limited effi-
cacy against established chronic stage disease, require
long courses of treatment (60 days) and have severe
side effects. With the reduction of transmission of
Chagas disease in several foci in S. America, there has
been greater focus on the needs for treatment of inde-
terminate and early chronic phases. Thorough experimen-
tal studies show that persistence of parasites, coupled
with an imbalanced immune response that could include
autoimmune reactions, generate sustained inflammatory
responses in infected tissues producing the characte-
ristic lesions of chronic Chagas disease (Tarleton et al.,
2001). Significant reduction of T. cruzi from infected
patients appears, therefore, to be essential to prevent
disease progression and to avert its irreversible long-
term consequences. Studies with benznidazole have
shown that it has some efficacy in early chronic infec-
tions (Sosa-Estani et al., 1998), and a long term clinical
trial (BENEFIT) is now underway to determine the
extent of use of this drug for this indication (http://cli-
nicaltrials.gov/show/NCT00123916). There are several
rational approaches to the treatment of Chagas disease
that have identified novel compounds or the potential
for therapeutic switching. The potential of specific
ergosterol biosynthesis inhibitors that act at the level
of C14α sterol demethylase, has long been known, and
some like ketoconazole entered clinical studies decades
ago. However, studies by Urbina and colleagues have
shown that new anti-fungal triazole derivatives (Fig. 1),
for example posoconazole, have very high potency
against T. cruzi, and are capable of curing chronic
infections in mice (Molina et al., 2000). One of this
drug class will certainly enter clinical trials. Other novel
ergosterol biosynthesis inhibitors that act at the level
of squalene synthase or oxidosqualene cyclase (Urbina
& Docampo, 2003) also show potential. Inhibitors of
cruzipain, an essential protease specific to the parasite
(Cazzulo et al., 2002) and one particular vinyl sul-
phone, K777, is in pre-clinical development (Doyle et
al., 2007). Other studies have identified inhibitors of
targets on the isoprenoid biosynthesis pathway, inclu-
ding farnesyl transferase and farnesyl pyrophosphate
synthase. N-alkyl-bisphosphonates, inhibitors of far-
nesyl that selectively accumulate in the parasite’s aci-
docalcisomes, also have activity in experimental models
(Garzoni et al., 2004).
DISCUSSION
The recent publication of the genome sequencesof the pathogens that cause leishmaniasis andtrypanosomiasis helps to identify both similari-
ties as well as differences in potential drug targets. The
subtle differences between the parasites in their meta-
bolic adaptations, the required pharmacokinetic pro-
perties of drugs for the different sites of infection, and
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the different approaches required for acute and chronic
infections, indicates that we are not in the business of
discovering one drug. Each of these three diseases will
require several drugs or formulations of drugs for the
treatment of all their manifestations. The discovery and
development of these new drugs will require: i) increa-
sed input from the disciplines of chemistry, pharma-
cology, toxicology and pharmaceutics, and ii) further
development of suitable disease models and methods
for progressing leads and candidate drugs through
pre-clinical studies. The limited progress in drug deve-
lopment of the past decades is part of history. Changes
in donor patterns, in incentives in the new not-for-
profit model of drug development, in the engagement
of the pharmaceutical industry bode well for the future.
But this should not be taken for granted and the res-
ponsibility for a sustained effort in this field requires
effective teams, prioritization where necessary and
decisions.
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